Evidence map›Paper›PMID 36111239›Full record

ArticleFrontiers in cellular and infection microbiology2022

Carbohydrate-binding protein from stinging nettle as fusion inhibitor for SARS-CoV-2 variants of concern.

Emiel Vanhulle, Thomas D'huys, Becky Provinciael, Joren Stroobants, Anita Camps, Sam Noppen, Dominique Schols, Els J M Van Damme, Piet Maes, Annelies Stevaert and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
4.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 16 citations in OpenAlex.

  1. Integrated Evaluation ofPharmaceuticals (Basel, Switzerland) · 2026
    Article
  2. Review
  3. Article
  4. Stinging Nettle (Plants (Basel, Switzerland) · 2025
    Review
  5. Cyanovirin-N Binding toBiochemistry · 2024
    Article
  6. The biological function ofFrontiers in veterinary science · 2024
    Review
  7. Article
  8. Article
  9. Pharmaceutics · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Emiel VanhulleLaboratory of Virology and Chemotherapy, Rega Institute, Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium.
Thomas D'huysLaboratory of Virology and Chemotherapy, Rega Institute, Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium.
Becky ProvinciaelLaboratory of Virology and Chemotherapy, Rega Institute, Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium.
Joren StroobantsLaboratory of Virology and Chemotherapy, Rega Institute, Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium.
Anita CampsLaboratory of Virology and Chemotherapy, Rega Institute, Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium.
Sam NoppenLaboratory of Virology and Chemotherapy, Rega Institute, Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium.
Dominique ScholsLaboratory of Virology and Chemotherapy, Rega Institute, Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium.
Els J M Van DammeLaboratory of Biochemistry and Glycobiology, Department of Biotechnology, Ghent University, Ghent, Belgium.
Piet MaesLaboratory of Clinical and Epidemiological Virology, Rega Institute, Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium.
Annelies StevaertLaboratory of Virology and Chemotherapy, Rega Institute, Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium.
Kurt VermeireLaboratory of Virology and Chemotherapy, Rega Institute, Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium.
KU Leuven · BERega Institute for Medical Research · BEGhent University · BE

Funding

Resource for Biocomputing Visualization and InformaticsP41GM103311 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI FERRIN, THOMAS E · 2012 to 2017
$8.2M
NIGMS NIH HHS P41 GM103311
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

COVID-19Urtica dioicaAngiotensin-Converting Enzyme 2Anti-Retroviral AgentsAntiviral AgentsCarbohydratesEuropiumHumansReceptors, Cell SurfaceSARS-CoV-2Spike Glycoprotein, CoronavirusViral ProteinsAngiotensin-Converting Enzyme 2Anti-Retroviral AgentsAntiviral AgentsCarbohydratesEuropiumReceptors, Cell Surfacesaccharide-binding proteinsSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Viral Proteinsfusion inhibitorlectinN-acetylglucosamine (GlcNAc)SARS-CoV-2spike proteinUDA

Identifiers

PMID36111239
PMCPMC9468479
OpenAlexW4293538592

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.